N,N-diethyl-N'-methyl-butanediyldiamine | 74332-29-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N,N-diethyl-N'-methyl-butanediyldiamine
• 英文别名: N,N-Diaethyl-N'-methyl-butandiyldiamin；Diethyl[4-(methylamino)butyl]amine；N',N'-diethyl-N-methylbutane-1,4-diamine
• CAS: 74332-29-9
• 化学式: C₉H₂₂N₂
• mdl: MFCD12161265
• 分子量: 158.287
• InChiKey: JSMPEGRPXGJWRD-UHFFFAOYSA-N

物化性质

• 沸点：
  97 °C(Press: 42 Torr)
• 密度：
  0.819±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N,N-diethyl-N'-methyl-butanediyldiamine 、 N,N-二乙基氯甲酰胺 生成 N,N-diethyl-N'-(4-diethylamino-butyl)-N'-methyl-urea
  参考文献：
  名称：

  Wadia et al., Journal Of Scientific and Industrial Research, 1958, vol. 17B, p. 11,20

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 lithium aluminium tetrahydride 、 乙醚 作用下， 生成 N,N-diethyl-N'-methyl-butanediyldiamine
  参考文献：
  名称：

  Wadia et al., Journal Of Scientific and Industrial Research, 1958, vol. 17B, p. 11,20

  摘要：

  DOI：

文献信息

• [EN] 3-PHENYLSULPHONYL-QUINOLINE DERIVATIVES AS AGENTS FOR TREATING PATHOGENIC BLOOD VESSELS DISORDERS<br/>[FR] DÉRIVÉS DE 3-PHÉNYLSULFONYL-QUINOLÉINE EN TANT QU'AGENTS POUR LE TRAITEMENT DE TROUBLES DES VAISSEAUX SANGUINS PATHOGÈNES
  申请人：UNIV CALIFORNIA

  公开号：WO2021076886A1

  公开（公告）日：2021-04-22

  The disclosure provides compounds, and compositions, including pharmaceutical compositions, kits that include the compounds, and methods of using (or administering) and making the compounds. The disclosure further provides compounds or compositions thereof for use in a method of modulating PLXDC1 (TEM7) and/or PLXDC2 or killing pathogenic blood vessles. The disclosure further provides compounds or compositions thereof for use in a method of treating a disease, disorder, or condition that is mediated, at least in part, by PEDF receptors or by angiogenesis.

  该披露提供了化合物和组合物，包括药物组合物、包含这些化合物的试剂盒，以及使用（或给药）和制备这些化合物的方法。该披露进一步提供了用于调节PLXDC1（TEM7）和/或PLXDC2或杀灭病原性血管的方法中的化合物或其组合物。该披露还提供了用于治疗由PEDF受体或血管生成至少部分介导的疾病、紊乱或状况的方法中的化合物或其组合物。
• PROCESS FOR PRODUCING MACROLIDE COMPOUND AND INTERMEDIATE THEREFOR
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP2168961A1

  公开（公告）日：2010-03-31

  The present invention provides a method for producing a 12-membered ring macrolide compound expected as a prophylactic or therapeutic agent for solid tumors and the like, and a production intermediate thereof. In detail, by acetalizing hydroxyl groups at 6- and 7-positions of a 12-membered ring macrolide compound being a raw material with dialkyl tin (IV) oxide and, after that, reacting the product with a carbamoyl halide derivative, the 7-position urethane derivative of the 12-membered ring macrolide compound being the target is effectively produced, without protecting hydroxyl groups at other positions.

  本发明提供了一种生产预期作为固体肿瘤等疾病的预防或治疗剂的12元环大环内酯化合物的方法，以及其生产中间体。具体而言，通过将作为原料的12元环大环内酯化合物的6-和7-位置的羟基与二烷基锡（IV）氧化物缩醛化，然后将产物与氨基甲酰卤衍生物反应，有效地生产了目标为12元环大环内酯化合物的7-位置脲酯衍生物，而无需保护其他位置的羟基。
• Novel physiologically active substances
  申请人：Kotake Yoshihiko

  公开号：US20050245514A1

  公开（公告）日：2005-11-03

  Compounds represented by the following general formula (I), pharmacologically acceptable salts thereof or hydrates of the same: (I) wherein W represents and R 3 , R 7 , R 16 , R 17 , R 20 , R 21 and R 21′ are the same or different and each represents hydrogen, etc. Because of inhibiting angiogenesis and inhibiting the production of VEGF particularly in hypoxia, the compounds (I) are useful as remedies for solid cancer.

  具有下述通式(I)表示的化合物、其药理学上可接受的盐或水合物：(I)其中W代表，R3、R7、R16、R17、R20、R21及R21'相同或不同，各自代表氢等。由于能抑制血管生成及在缺氧条件下抑制VEGF的产生，化合物(I)可作为实体癌症的治疗药物。
• [EN] PROCESS FOR PRODUCING CARBAMOYLOXY (METH)ACRYLATES AND NEW CARBAMOYLOXY (METH)ACRYLATES<br/>[FR] PROCESSUS DE PRODUCTION DE (METH)ACRYLATES CARBAMOYLOXY ET DE NOUVEAUX (METH)ACRYLATES CARBAMOYLOXY
  申请人：UCB SA

  公开号：WO2004052843A1

  公开（公告）日：2004-06-24

  The invention relates to a process for producing carbamoyloxy (meth)acrylates which comprises transesterification of hydroxyalkyl carbamates with an (meth)acrylate of formula CH2=CR29-COOR30 wherein R29 is hydrogen or methyl and R30 represents an alkyl group comprising from 1 to 8 carbon atoms, in the presence of an organotitanate, an organozirconate catalyst or an organotin catalyst, the carbamoyloxy (meth)acrylates thereby obtained and their use in radiation curable compositions.

  该发明涉及一种生产羰酰氧基（甲基）丙烯酸酯的方法，包括将羟基烷基氨基甲酸酯与具有化学式CH2=CR29-COOR30的（甲基）丙烯酸酯进行酯交换反应，其中R29为氢或甲基，R30代表含有1至8个碳原子的烷基基团，在有机钛、有机锆或有机锡催化剂的存在下进行，从而得到羰酰氧基（甲基）丙烯酸酯，并将其用于辐射固化组合物中。
• 12 MEMBERED-RING MACROLACTAM DERIVATIVES
  申请人：Miyano Masayuki

  公开号：US20080312317A1

  公开（公告）日：2008-12-18

  There provided a 12-membered-ring macrolactam derivative having antitumor activity: A compound represented by Formula (1) or a salt thereof. In this Formula, R 1 is a hydrogen atom, a C 1-6 alkyl group, a C 1-6 alkylcarbonyl group or a C 6-14 arylcarbonyl group; R 2 is a hydrogen atom or a C 1-6 alkyl group; R 3 is a hydrogen atom or a hydroxyl group; R 4 is a hydrogen atom or a hydroxyl group; R 5 is a hydrogen atom or a C 1-6 alkyl group; R 6 is a hydrogen atom or a hydroxyl group; and R 7 is an acetyl group or the like.

  提供了一种具有抗肿瘤活性的12-成员环大环内酰胺衍生物：由化学式（1）表示的化合物或其盐。在该化学式中，R1是氢原子、C1-6烷基基团、C1-6烷基羰基基团或C6-14芳基羰基基团；R2是氢原子或C1-6烷基基团；R3是氢原子或羟基；R4是氢原子或羟基；R5是氢原子或C1-6烷基基团；R6是氢原子或羟基；R7是乙酰基或类似物。